Aerie Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aerie Pharmaceuticals generated cash of -$99,154,000, which is less than the previous year. Cash used in financing activities reached the amount of $2,972,000 last year. Net change in cash is therefore -$114,383,000.
Cash Flow
| 2012 | -14.96M | -51K | 2.87M |
|---|---|---|---|
| 2013 | -16.44M | -63K | 83.23M |
| 2014 | -33.72M | -73.31M | 122.98M |
| 2015 | -55.74M | 9.38M | 51.83M |
| 2016 | -79.84M | 18.1M | 168.62M |
| 2017 | -93.21M | -42.80M | 135.64M |
| 2018 | -152.57M | 20.78M | 137.03M |
| 2019 | -150.43M | -183.24M | 274.79M |
| 2020 | -64.69M | 73.17M | -859K |
| 2021 | -99.15M | -18.20M | 2.97M |
AERI Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 151.57M | 143.94M | 202.81M | 197.56M | 197.94M | 91.06M | 85.58M | 69.64M | 2.92M | 15.06M |
Operating activities | ||||||||||
Net income | -74.81M | -183.10M | -199.58M | -232.56M | -145.10M | -99.05M | -74.36M | -48.13M | -31.14M | -14.97M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 37.5M | 34.15M | 18.11M | 2.44M | 1.41M | 970K | 252K | 73K | 64K | 138K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.85M | 430K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.85M | 430K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -12.80M | -17.66M | -35.63M | -2.71M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -12.10M | -5.16M | -10.25M | -9.68M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 21.58M | 16.86M | -270.75M | 26.58M | 925K | 2.47M | 5.38M | 4.82M | 2.04M | -1.27M |
Cash generated by operating activities | -99.15M | -64.69M | -150.43M | -152.57M | -93.21M | -79.84M | -55.74M | -33.72M | -16.44M | -14.96M |
Investing activities | ||||||||||
Purchases Of Investments | -132.36M | -116.59M | -165.45M | -56.19M | -104.49M | -35.16M | -46.87M | -95.37M | 0 | 0 |
Investments In Property Plant And Equipment | -3.29M | -3.1M | -9.95M | -31.31M | -15.97M | -5.07M | -3.28M | -181K | -63K | -51K |
Acquisitions Net | 0 | 0 | 0 | 0 | -10.5M | 5.60M | 3.85M | 597K | 0 | 0 |
Cash generated by investing activities | -18.20M | 73.17M | -183.24M | 20.78M | -42.80M | 18.1M | 9.38M | -73.31M | -63K | -51K |
Financing activities | ||||||||||
Common Stock Issued | 2.97M | -859K | 684K | 135.97M | 134.21M | 168.47M | 50.45M | 0 | 71.87M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -130K |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -8.27M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.97M | -859K | 274.79M | 137.03M | 135.64M | 168.62M | 51.83M | 122.98M | 83.23M | 2.87M |
Net Change In Cash | -114.38M | 7.63M | -58.87M | 5.24M | -376K | 106.88M | 5.47M | 15.93M | 66.72M | -12.14M |
Cash at end of period | 37.18M | 151.57M | 143.94M | 202.81M | 197.56M | 197.94M | 91.06M | 85.58M | 69.64M | 2.92M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |